The Fast MDx Platform

Fully automated safe testing with inactivate samples aspirated from the sealed Pathtubes® inside the Fast MDx platform.

The first fully automated Festo High-Throughput MDx liquid handling system, has been  designed and optimized to work with the ultra-fast qPCR NGx2 thermal cycler.

Approved cyber security and fully integration into healthcare provider Laboratory Information Management Systems (LIMS).

Manufacturing under a BSi audited ISO13485 Quality Management System.

The Fast MDx platform has been designed to be manufactured initially with MHRA and CE-IVDr and subsequently with FDA regulatory approval.

Testing

Fast MDx will launch in late 2022 with a CE-IVDr approved high-throughput syndromic respiratory test for flu A, flu B, RSV A, RSV B and COVID-19.

Blood testing for prenatal detection of Rhesus D genotype and early cancer detection of free circulating tumour cells in blood will be available on the platform in 2023.

All tests will be MHRA and CE-IVDr approved when launched.